TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas

Diagnostic Molecular Pathology

Volumn 9, Issue 1, 2000, Pages 41-46

  Della Torre, Gabriella ^a   Pasquini, Graziella ^a   Pilotti, Silvana ^a   Alasio, Loredana ^a   Civelli, Enrico ^a   Cozzi, Guido ^a   Milella, Marco ^a   Salvetti, Monica ^a   Pierotti, Marco A ^a   Severini, Aldo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Human cholangiocarcinoma; mdm2 p53 immunophenotype; p16(ink4) CDKN2 gene mutations; TP53 gene mutations

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; BASE SEQUENCE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034050388     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-200003000-00007     Document Type: Article

References (31)

1. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34.
2. Blagosklonny MV. Loss of function and p53 protein stabilization. Oncogene 1997;15:1889-93.
3. Capoulade C, Bressac-de Paillerets B, Lefrere I, et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 1998;16: 1603-10.
4. Choi SW, Hytiroglou P, Geller SA, et al. The expression of p53 antigen in primary malignant epithelial tumors of the liver: an immunohistochemical study. Liver 1993;13:172-6.
5. Hartmann A, Blaszyk H, McGover RM, et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 1995;10:681-8.
6. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
7. Kiba T, Tsuda H, Pairojkul C, Inoue S, Sugimura T, Hirohashi S. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993;8:312-8.
8. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
9. Lavarino C, Corletto V, Mezzelani A, et al. Detection of tp53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. Br J Cancer 1998;77:125-30.
10. Lavarino C, Delia D, Di Palma S, Zunino F, Pilotti S. p53 in drug resistance in ovarian cancer. Lancet 1997;349:1556.
11. Lozano G, Montes de Oca Luna R. MDM2 function. Biochim Biophys Acta 1998;1377:M55-9.
12. Meltzer PS. MDM2 and p53: a question of balance. J Natl Cancer Inst 1994;86:1265-6.
13. Milella M, Salvetti M, Cerrotta AM, et al. International radiology and radiotherapy for unoperable cholangiocarcinoma of the extrahepatic bile ducts. Tumori 1998;84:467-71.
14. Momand J, Zambetti GP. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 1996;12:2279-89.
15. Ohashi K, Nakajima Y, Kanehiro H, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995;109: 1612-7.
16. Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev 1993;2:537-44.
17. Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene 1997;15:1001-10.
18. Pilotti S, Della Torre G, Lavarino C, et al. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for différent pathogenetic mechanisms. J Pathol 1997;181:14-24.
19. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-9.
20. Righetti SC, Della Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplat-in-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93.
21. Selivanova G, Wiman KG. p53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 1995;66:143-80.
22. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996;2:912-7.
23. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994;57:1-9.
24. Storto PD, Saidman SL, Demetris AJ, Letessier E, Whiteside TL, Gollin SM. Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes Cancer 1990;2:300-10.
25. Terada T, Nakanuma Y. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas. Pathol Int 1996;46:764-70.
26. Thamavit W, Pairojkul C, Tiwawech D, Shirai T, Ito N. Strong promoting effect of Opisthorchis viverrini infection on dimethylnitrosamine-initiated hamster liver. Cancer Lett 1994;78:121-5.
27. Tsuda H, Satarug S, Bhudhisawasdi V, et al. Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Mol Carcinog 1992;6:266-9.
28. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-3.
29. Villa R, Gornati D, Zaffaroni N, Veneroni S, Bidoli P, Severini A. Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents. Anticancer Res 1997;17:961-8.
30. Washington K, Gottfried MR. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver 1996;16:99-104.
31. Yoshida S, Todoroki T, Ichikawa Y, et al. Mutations of p16Ink4/ CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995;55:2756-60.